Retatrutide vs Tirzepatide

How they're alike

Retatrutide and tirzepatide are sibling molecules from the same Eli Lilly incretin program: both are long-acting, once-weekly subcutaneous synthetic peptides engineered as multi-receptor agonists on the proglucagon/GIP superfamily scaffold (Müller, Physiol Rev 2024). They share the same core engineering pattern — a glucagon-superfamily peptide backbone carrying a γGlu-linked C20 fatty diacid side chain on a lysine residue to drive reversible albumin binding and extend the circulating half-life to roughly a week, enabling once-weekly dosing. Local sequence alignment of the two molecules returns 71.4% identity over a 28-residue stretch at the N-terminus, reflecting their shared GIP-derived core. Both engage the GIP receptor and the GLP-1 receptor, reproducing the established incretin class effects — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and engagement of hypothalamic and brainstem satiety circuits — and both have been developed primarily for the obesity and type 2 diabetes indications (Madsbad and Holst 2025, Expert Opin Investig Drugs). At the safety-signal level, both share the GI-dominant adverse-event profile common to incretin-based drugs (nausea, vomiting, diarrhea, constipation), with events concentrating around dose escalations.

How they differ

The defining mechanistic difference is the receptor footprint. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and detailed pharmacological characterization shows it is an imbalanced and biased dual agonist with distinct potency and signaling properties at each of its two receptors (Willard et al., JCI Insight). Retatrutide adds a third arm — agonism at the glucagon receptor (GCGR) — to the same GIP+GLP-1 backbone. The glucagon-receptor signal, in the context of concurrent GIP and GLP-1 activation, is described as driving lipolysis, hepatic fatty-acid oxidation, thermogenesis, and a measurable rise in resting energy expenditure, without producing net hyperglycemia at the doses studied (Jastreboff et al., NEJM 2023). That additional thermogenic-lipolytic component is the proposed mechanistic basis for retatrutide's larger weight-loss magnitudes in Phase 2 and for its unusually large liver-fat reductions in metabolic dysfunction-associated steatotic liver disease (Sanyal et al., Nat Med 2024).

The two molecules also differ sharply in regulatory and evidence maturity. Tirzepatide has been FDA-approved since May 2022 (Mounjaro for type 2 diabetes), with subsequent approvals for chronic weight management (Zepbound, November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, December 2024), supported by a large Phase 3 program including the pivotal SURMOUNT-1 obesity trial of 2,539 adults that reported 22.5% mean weight loss at 15 mg over 72 weeks (Jastreboff et al., NEJM 2022). Retatrutide is investigational: its published human evidence base is concentrated in a Phase 2 obesity trial of 338 adults (Jastreboff et al., NEJM 2023), a Phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023), and a Phase 2a MASLD substudy (Sanyal et al., Nat Med 2024), with the eight-trial TRIUMPH Phase 3 program still reading out at dossier date. On safety-signal granularity, retatrutide carries two signals not prominent in the dual-agonist class — a roughly 21% incidence of dysesthesia at the 12 mg dose and a resting heart-rate elevation attributed to the glucagon-receptor component — both reported in the Phase 2 obesity trial (Jastreboff et al., NEJM 2023). Half-life differs modestly (~5 days for tirzepatide vs ~6 days for retatrutide), but both support once-weekly subcutaneous dosing.

Head-to-head clinical evidence

No randomized head-to-head trial directly comparing retatrutide and tirzepatide at maximal dose has been published in the dossier sources. The dossier's PubMed sweep for direct head-to-head papers returned zero candidates, and retatrutide's pivotal program (TRIUMPH) has not included tirzepatide as an active comparator in the readouts available. Cross-trial indirect comparisons are the only quantitative frame available. In Phase 2, retatrutide 12 mg once weekly produced 24.2% mean body-weight reduction at 48 weeks in adults with obesity (Jastreboff et al., NEJM 2023); tirzepatide 15 mg once weekly produced 22.5% mean body-weight reduction at 72 weeks in the larger Phase 3 SURMOUNT-1 trial (Jastreboff et al., NEJM 2022). Network meta-analyses of incretin-based therapies in the dossier place both molecules at the top of the weight-loss ranking, with retatrutide and tirzepatide consistently identified as the most effective agents and the two compared only indirectly via the placebo arms of their respective programs (Madsbad and Holst 2025). The pipeline review notes the methodological limits of cross-trial comparison and explicitly flags the absence of a maximal-dose head-to-head as a key open question for the field. Until a direct comparison reads out, any quantitative ranking of the two molecules carries the standard caveats of indirect comparison — population heterogeneity, trial-duration differences (the Phase 2 retatrutide trial ran 48 weeks; SURMOUNT-1 ran 72 weeks), and differences in titration cadence and adherence.

Safety profile comparison

The two drugs share most of their safety frame and diverge on a small number of signals attributable to the glucagon-receptor arm. Both carry the GI-dominant tolerability profile of the incretin class (nausea, vomiting, diarrhea, constipation, decreased appetite), concentrated around dose escalations and typically attenuating thereafter. Both share class-level cautions for pancreatitis and gallbladder events, and both carry the medullary thyroid C-cell tumor concern inherited from rodent C-cell findings across the incretin class. Tirzepatide's FDA label additionally formalizes a boxed warning for medullary thyroid carcinoma, absolute contraindication in personal or family history of MTC or MEN2, and label-level cautions on altered absorption of oral co-medications and on reduced efficacy of oral hormonal contraceptives following each dose escalation.

The retatrutide-specific signals come from the glucagon-receptor component. The Phase 2 obesity trial reported a ~21% incidence of dysesthesia (tingling, burning, pin-and-needle sensations in extremities) at the 12 mg dose, described as a novel signal not prominent in the GLP-1 or GIP/GLP-1 class, with mechanism unclear (Jastreboff et al., NEJM 2023). The same trial reported a treatment-discontinuation rate of roughly 18% at the 12 mg dose, and a resting heart-rate elevation of approximately +2 to +6 bpm attributed to glucagon-receptor activation. Transient modest fasting-glucose excursions at higher doses have also been reported and are under continued evaluation in the Phase 3 program (Rosenstock et al., Lancet 2023). Long-term safety follow-up beyond ~88 weeks has not been published for either molecule; tirzepatide's published continuous Phase III exposure is currently capped around 88 weeks, and retatrutide's published trials all end at or before that duration.

Indication overview

Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro, May 2022), chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (Zepbound, November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, December 2024). It is also authorized for parallel indications by EMA, MHRA, Health Canada, and TGA. Mechanistic underpinnings of the GIP receptor side of the molecule continue to be reviewed in the context of obesity and T2DM (Bailey and Flatt, Peptides 2024). Retatrutide has not been approved by FDA, EMA, MHRA, Health Canada, or TGA as of the dossier date — its human exposure occurs only inside Eli Lilly's TRIUMPH Phase 3 program. Positive topline readouts have been reported for TRIUMPH-4 (adults with obesity and knee osteoarthritis) and TRANSCEND-T2D-1 (adults with type 2 diabetes), with dedicated cardiovascular, MASH, sleep apnea, and hypertension readouts still pending. Independent academic replication of the retatrutide evidence base outside the single sponsor program is not yet available, and pipeline reviews place retatrutide alongside tirzepatide and other emerging polyagonists in active comparison (Madsbad and Holst 2025). Direct head-to-head data against tirzepatide at maximal dose are not yet published, leaving any quantitative comparison between the two molecules in the indirect-comparison frame.